Figure 2: CD4+ T-cell count rises in MOTIVATE 1 and 2 clinical trials in subjects who a) achieved plasma HIV-1-RNA <50 copies/mL at least once and, b) never achieved HIV-1-RNA <50 copies/mL. Longitudinal model of CD4+ cell count over time, with week, treatment, and week/treatment interaction as model terms; LOCF used for missing values. MVC: Maraviroc; PBO: placebo; OBT: optimized background treatment. P<0.05 for different effect of treatment over time, combined MVC arms vs PBO (5).